ClinicalTrials.gg
RecruitingNCT07423546Updated Jul 14, 2026

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

A Phase 1/2 interventional study of Xanomeline and trospium chloride (KarXT) in SCHIZOPHRENIA 1 (Disorder) and Schizoaffecitve Disorder, sponsored by New York State Psychiatric Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by New York State Psychiatric Institute · Phase 1/2, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Planned enrollment
18th of 20
12 · median 178
Started
2026
with 4 others
Phase 1/2
Only one
of the 20
Registered
18th of 20
by date
Lead sponsor
1 of 20
New York State Psychiatric Institute

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 18th largest by planned enrollment, is one of 5 that started in 2026, is the only one in phase 1/2, and was the 18th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. [18F]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission.

The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by [18F]DOPA Kicer ([18F]DOPA relative uptake rate)).

03

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)
  • Schizoaffecitve Disorder

Browse trials for

Keywords

  • Cobenfy
  • PET
  • MRI
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals aged 18 to 50, inclusive at screen
  2. Capable of understanding the study procedures and able to provide
  3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder
  4. Antipsychotic free at Visit 1 (by choice and for reasons unrelated to the study), and for at least 3 weeks (4 for aripiprazole, Cobenfy or LAIs) at the time of the baseline PET scan, inclusive of any antipsychotic-free time prior to consent
  5. PANSS total score > 80 and \< 120
  6. Willing to use qualified methods of (listed in section 5.3) for the study duration (for women of only)
  7. Stable dosing of herbal/dietary supplements for at least 6 weeks at the time of the first dose of Cobenfy and willingness to avoid products with known hepatotoxic ingredients (e.g., green tea extract, kratom, ashwagandha).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of moderate or severe substance use disorder within the previous month (from first PET scan)
  2. A history of poor or inadequate response to Cobenfy for any reason, to Cobenfy or trospium or no justifiable reason to expect improvement on Cobenfy, or treatment with Cobenfy within 4 weeks of the first PET Scan
  3. abnormality that is including a > 450 msec for men and > 470 msec for women, as corrected by the Fridericia formula (QTcF)
  4. Pregnant or breast-feeding women. Women of must have a negative serum β-hCG pregnancy test at Visit 1, must have been using an acceptable method of (section 5.3) for 30 days before the study, and must agree to do so for the whole study and 30 days after (unless or surgically sterile)
  5. Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety on study medication, including (but not necessarily limited to) the following: urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, hypernasality, resting heart rate >100 bpm or systolic Blood Pressure >150 mmHg, a history of orthostatic hypotension or abnormal orthostatic blood pressure (change in mean arterial pressure [1/3 systolic + 2/3 diastolic] of > 20% between supine and standing blood pressures), known (i.e., by history), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, symptomatic gallstone disease, active hepatic infections, history of bladder stones, recurrent urinary tract infections, or International Prostate Symptom Score > 7 or any one item > 2 (not including the nocturia item).
  6. Any material in the body that is a for MRI procedures or participated in prior nuclear medicine procedures in the past year that exceed FDA-defined limits when combined with radiation dosimetry from PET scanning in this protocol to avoid exceeding annual dosimetry limits (metal screener repeated before MRI scan during visit 2)
  7. Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the past 1 month or suicidal behavior in the past 3 months
  8. Laboratory abnormality that would compromise the well-being of the participant, including (AST) or alanine aminotransferase (ALT) value > 2 times the upper limit of the laboratory normal reference range, elevated (i.e., >2 x (ULN)), or serum prostate specific antigen (PSA) >10 ng/ml (for men only).
  9. A history of treatment resistance to antipsychotics
  10. Use of nicotine products within the previous month (prior to first PET scan)
  11. History of significant violent behavior when antipsychotic-free or currently homicidal
  12. Positive toxicology screen for any substances of abuse
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Xanomeline 50 mg and trospium chloride 20mg (KarXT)

    5 weeks of xanomeline 50mg/trospium 20mg bid (low dose arm).

    Drug: Xanomeline and trospium chloride (KarXT)

  • Experimental
    Xanomeline 100 mg and trospium chloride 20mg (KarXT)

    5 weeks of xanomeline 100mg/trospium 20mg bid (middle dose arm).

    Drug: Xanomeline and trospium chloride (KarXT)

  • Experimental
    Xanomeline 125 mg and trospium chloride 30mg (KarXT)

    5 weeks of xanomeline 125mg/trospium 30mg bid (high dose arm).

    Drug: Xanomeline and trospium chloride (KarXT)

Interventions

  • DrugXanomeline and trospium chloride (KarXT)

    Drug pages: XanomelineStudies of XanomelineXanomeline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Trospium chlorideStudies of Trospium chlorideTrospium chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be randomized to 5 weeks of low, middle, or high dose of Xanomeline and trospium chloride, and will complete a PET scan with \[18\]F DOPA at the beginning and end of the treatment period.

    Also known as: Cobenfy

06

What researchers measure

Primary outcomes

  1. [18F]DOPA Kicer ([18F]DOPA relative uptake rate)

    Time frame: Pre/post 5 weeks of Xanomeline and trospium chloride (KarXT)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data may be shared with direct and valid request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07423546
Responsible party
Joshua Kantrowitz (Principal Investigator, New York State Psychiatric Institute) — Principal investigator
First posted
Feb 20, 2026
Start date
Jul 1, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Shannon Peleg
Contact
shannon.peleg@nyspi.columbia.edu
646-774-8477
Joshua T Kantrowitz, MD
principal investigator · New York State Psychiatric Institute
Ragy Girgis, MD
principal investigator · New York State Psychiatric Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion